TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in tissue repair throughout the body. Research focuses on wound healing, tissue regeneration, and reducing inflammation.
Verified sources for TB-500 (Thymosin Beta-4 Fragment)
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of TB-500 (Thymosin Beta-4 Fragment)
Promotes tissue repair and regeneration by regulating actin dynamics, enhancing cell migration, and stimulating new blood vessel formation.
G-actin sequestration regulates cytoskeletal dynamics, supporting cell shape, movement, and division for wound repair.
Promotes migration of endothelial cells, keratinocytes, and fibroblasts to injury sites (proposed), which may accelerate wound healing.
Stimulates new blood vessel formation through endothelial cell activation, improving blood supply to healing tissues.
Enhances capillary tube formation and vascular network development (proposed), which may support tissue oxygenation.
Reduces inflammatory cytokine release and inhibits NF-κB signaling (proposed), which may limit excessive inflammation during repair.
Modulates extracellular matrix remodeling, influencing collagen deposition patterns during healing
Read Full TB-500 (Thymosin Beta-4 Fragment) Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Injury, Repair & Recovery
UPDATE: FDA Picks 7 Peptides for July 2026 Reclassification Vote
The FDA will vote on reclassifying BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax for pharmacy compounding at the July 23-24 PCAC meeting.
Best Peptides for Hair Growth: What Actually Works
GHK-Cu, PTD-DBM, and other peptides for hair growth ranked by research evidence. What the science says, what's proven, and what's still hype.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.